E V Tsyrlina Selected Research

E V Tsyrlina Research Topics

Disease

28	Neoplasms (Cancer) 01/2016 - 01/2000
21	Breast Neoplasms (Breast Cancer) 01/2016 - 01/2000
8	Endometrial Neoplasms (Endometrial Cancer) 01/2005 - 01/2000
4	Insulin Resistance 01/2006 - 01/2000
4	Carcinogenesis 08/2001 - 01/2000
3	Body Weight (Weight, Body) 01/2004 - 01/2003
2	Disease Progression 01/2008 - 01/2003
2	Adenocarcinoma 11/2004 - 04/2003
1	Ovarian Cysts (Ovarian Cyst) 01/2016
1	Amenorrhea 01/2012
1	Thyroid Neoplasms (Thyroid Cancer) 01/2008
1	Neoplasm Metastasis (Metastasis) 01/2006
1	Type 2 Diabetes Mellitus (MODY) 01/2005
1	Diabetes Mellitus 11/2004
1	Aneuploidy (Aneuploid) 01/2001
1	Uterine Neoplasms (Uterine Cancer) 01/2001
1	Hyperinsulinism (Hyperinsulinemia) 01/2000
1	Obesity 01/2000

Drug/Important Bio-Agent (IBA)

18	Estrogens (Estrogen)FDA Link 01/2008 - 01/2000
14	Hormones (Hormone)IBA 01/2016 - 01/2000
12	Estradiol (Delestrogen)FDA LinkGeneric 01/2016 - 01/2000
11	Progesterone Receptors (Progesterone Receptor)IBA 01/2010 - 01/2001
7	Estrogen ReceptorsIBA 01/2010 - 01/2003
7	Aromatase (CYP19)IBA 01/2008 - 01/2001
5	Tamoxifen FDA LinkGeneric 01/2016 - 01/2001
4	SteroidsIBA 01/2014 - 01/2000
4	Insulin (Novolin)FDA Link 01/2010 - 01/2000
4	Biological ProductsIBA 01/2008 - 01/2001
4	Glucose (Dextrose)FDA LinkGeneric 01/2008 - 01/2000
4	Progesterone FDA LinkGeneric 01/2008 - 01/2001
4	Steroid Receptors (Steroid Receptor)IBA 03/2006 - 04/2003
4	Letrozole (Femara)FDA LinkGeneric 01/2006 - 01/2001
4	Aromatase InhibitorsIBA 01/2005 - 01/2001
3	CholesterolIBA 01/2008 - 01/2003
3	DNA (Deoxyribonucleic Acid)IBA 03/2006 - 04/2003
3	EnzymesIBA 01/2005 - 01/2001
3	Estrogen Receptor alphaIBA 11/2004 - 06/2003
3	Catechol EstrogensIBA 01/2001 - 01/2000
2	Proteins (Proteins, Gene)FDA Link 01/2014 - 06/2003
2	LipidsIBA 01/2014 - 01/2001
2	Interleukin-6 (Interleukin 6)IBA 01/2008 - 01/2006
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2008 - 01/2006
2	exemestane (Aromasin)FDA Link 01/2005 - 11/2004
2	Estrogen Receptor Modulators (Antiestrogen)IBA 11/2004 - 01/2001
2	Estrogen Receptor betaIBA 11/2004 - 11/2003
2	C-PeptideIBA 11/2004 - 01/2000
2	Mixed Function Oxygenases (Monooxygenases)IBA 01/2004 - 01/2000
1	Membrane LipidsIBA 01/2014
1	pyreneIBA 01/2014
1	Indicators and Reagents (Reagents)IBA 01/2014
1	1,1'- (4,4,7,7- tetramethyl- 4,7- diazaundecamethylene)bis- 4- (3- methyl- 2,3- dihydro(benzo- 1,3- thiazole)- 2- methylidene)quinolinium (TOTO)IBA 01/2013
1	hydroxide ionIBA 01/2013
1	Testosterone (Sustanon)FDA Link 01/2012
1	BiguanidesIBA 01/2010
1	Metformin (Glucophage)FDA LinkGeneric 01/2010
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2010
1	8-Hydroxy-2'-DeoxyguanosineIBA 01/2008
1	LeptinIBA 01/2008
1	AdiponectinIBA 01/2008
1	Phenobarbital (Luminal)FDA Link 01/2008
1	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2008
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2006
1	AldehydesIBA 01/2006
1	beta-NaphthoflavoneIBA 07/2005
1	Messenger RNA (mRNA)IBA 11/2004
1	Anastrozole (Arimidex)FDA LinkGeneric 11/2004
1	TransferasesIBA 01/2004
1	catechol (pyrocatechol)IBA 01/2004
1	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA 01/2004
1	AndrogensIBA 11/2003
1	Ethanol (Ethyl Alcohol)IBA 08/2001
1	Free RadicalsIBA 01/2001
1	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 01/2001
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2001
1	SmokeIBA 01/2001
1	CamedonIBA 01/2001
1	Progestins (Progestagens)IBA 01/2001
1	estrogen 2-hydroxylaseIBA 01/2000

Therapy/Procedure

11	Therapeutics 01/2014 - 01/2001
2	Neoadjuvant Therapy 01/2012 - 01/2001
2	Estrogen Replacement Therapy 01/2001 - 03/2000
2	Aftercare (After-Treatment) 01/2001 - 01/2001
1	Precision Medicine 01/2016
1	Adjuvant Chemotherapy 01/2012
1	Duration of Therapy 01/2005